Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Exagen Inc. reported a quarterly loss of $0.20 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.19 per share a year ago [1] - The company achieved revenues of $15.5 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 8.38% and up from $14.42 million year-over-year [2] - Exagen shares have increased approximately 46.8% since the beginning of the year, contrasting with a -3.3% decline in the S&P 500 [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - Exagen has also topped consensus revenue estimates three times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $15.5 million, and for the current fiscal year, it is -$0.57 on revenues of $64.4 million [7] Market Outlook - The sustainability of Exagen's stock price movement will largely depend on management's commentary during the earnings call [3] - The estimate revisions trend for Exagen is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, which may impact stock performance [8]